- Home
- ACIU vs CPS Comparison
ACIU vs CPS Comparison
Compare ACIU & CPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- CPS
- Stock Information
- Founded
- ACIU 2003
- CPS 1960
- Country
- ACIU Switzerland
- CPS United States
- Employees
- ACIU N/A
- CPS N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- CPS Auto Parts:O.E.M.
- Sector
- ACIU Health Care
- CPS Consumer Discretionary
- Exchange
- ACIU Nasdaq
- CPS Nasdaq
- Market Cap
- ACIU 213.3M
- CPS 462.2M
- IPO Year
- ACIU 2016
- CPS N/A
- Fundamental
- Price
- ACIU $2.43
- CPS $37.84
- Analyst Decision
- ACIU Strong Buy
- CPS Hold
- Analyst Count
- ACIU 2
- CPS 1
- Target Price
- ACIU $10.00
- CPS $12.00
- AVG Volume (30 Days)
- ACIU 131.3K
- CPS 227.6K
- Earning Date
- ACIU 11-04-2025
- CPS 10-30-2025
- Dividend Yield
- ACIU N/A
- CPS N/A
- EPS Growth
- ACIU N/A
- CPS N/A
- EPS
- ACIU N/A
- CPS 1.65
- Revenue
- ACIU $36,362,036.00
- CPS $2,719,148,000.00
- Revenue This Year
- ACIU N/A
- CPS $2.46
- Revenue Next Year
- ACIU $1,022.98
- CPS $3.29
- P/E Ratio
- ACIU N/A
- CPS $22.98
- Revenue Growth
- ACIU 86.71
- CPS N/A
- 52 Week Low
- ACIU $1.43
- CPS $10.38
- 52 Week High
- ACIU $3.98
- CPS $39.79
- Technical
- Relative Strength Index (RSI)
- ACIU 62.18
- CPS 70.72
- Support Level
- ACIU $2.12
- CPS $37.24
- Resistance Level
- ACIU $2.35
- CPS $39.67
- Average True Range (ATR)
- ACIU 0.13
- CPS 1.51
- MACD
- ACIU 0.03
- CPS -0.11
- Stochastic Oscillator
- ACIU 97.56
- CPS 69.63
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.